<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Nanoparticles: The Trojan Horse That Defeats Ovarian Cancer By Releasing Dendritic Cells

Image of the Trojan Horse

Death rate in ovarian cancer has remained the same over the last 40 years because there has been little improvement in therapeutic strategies. A new study authored by a team or researchers at Cornell University and recently published in Cell offers a beacon of hope by showing that the immune system can be instructed to act as a first line of defense against ovarian cancer.

Ovarian cancer is a very heterogeneous disease that includes many molecular subtypes, driven by a number of different genetic alterations. It has long been known as a silent killer because symptoms usually manifest only at an advanced stage when treatment is rarely curative. For this reason much emphasis has been given to new ways of screening early ovarian cancer by trying to identify novel biomarkers or performing more frequent scans.

Surgery is the main treatment for most ovarian cancers. The extent of ovaries and uterus tissue removal depends on the stage of ovarian cancer at diagnosis. Standard first line treatment consists in combination therapy of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol®) or docetaxel (Taxotere®). Unfortunately ninety percent of patients have a recurrence, which indicates that tumors do not respond in a meaningful way to repeated rounds of chemotherapy and surgery, usually leading to more aggressive surgery, chemotherapy, radiotherapy, and surveillance.

Apart from some experimental studies, ovarian cancer is not treated with immunotherapy. Since immune-based approaches have succeeded in other lethal cancers, such as melanoma, scientists have started investigating whether engaging the immune system may be
 beneficial to ovarian cancer patients too.

A team of researchers at Cornell University has realized that ovarian cancer becomes a very hypoxic environment, in other words the tumor itself and the microenvironment around it are starved for oxygen because of the fast growing pace of cancer cells. To survive in such a hostile environment tumor cells upregulate the XBP1 gene that helps them detoxify and keep them active and capable of proliferating. In a study published on Cell researchers found that in preclinical models of ovarian cancer, tumor associated dendritic cells (DCs), a type of immune cells, similarly to cancer cells start expressing XBP1 following oxygen starvation. However, while this keeps DCs healthy it also inhibits their antitumor activity. DCs are antigen presenting cells that incorporate and expose on their surface fragments of tumor cells to activate another type of immune cells, called T cells that ultimately execute cancer cell death. When DCs expresses XBP1 they can no longer activate T cells to fight tumor growth.

How Can We Prevent Immune Cells Inactivation?

To rescue the immune cells ability to fight tumors the Cornell team injected tumor bearing mice with nanoparticles acting as a Trojan Horse: DCs intercept these circulating nanoparticles and respond by eating them up, much like they would do if they were pathogens. Once incorporated by DCs, the nanoparticles release their load, an inhibitor that silences XBP1 expression in the immune cells and renders them capable of activating T cells.

The team is now devising first-in-class drugs that can inhibit the activity of XBP1 in cancer cells and DC, which would both sensitize the cancer to treatment and restore an immune response against it.

Crown Bioscience has a longstanding interest in ovarian cancer research and is intrigued by the application of immunotherapy to novel types of cancer where its efficacy is currently being tested. Crown Bioscience has developed several highly predictive ovarian cancer models for preclinical drug evaluation included in our HuPrime® and PDXact™ collections of patients derived xenografts (PDX). Our immunotherapy resources include a range of platforms, with either murine or human immunity such as syngenic (bioluminescent and metastatic) modelsGEMM, MuPrime™ (the murine version of HuPrime® ), HuMice (humanized mice produced through inoculating human hematopoietic cells into immunocompromised mice), and MiXeno (creating transient human immunity by mixing human peripheral blood mononucleated cells with xenograft models). We also support preclinical drug development through the use of our in vivo grade human and mouse isotype control antibodies.

Contact us today at busdev@crownbio.com to discuss how can we help driving forward your ovarian cancer research.

 


Related Posts